Opioid Use Disorder Across a Hospital-to-Clinic Transition

Learning objectives#

• Distinguish opioid withdrawal, opioid intoxication or overdose, pain, infection, medication effects, and concurrent substance withdrawal during a care transition.
• Compare buprenorphine, methadone, and naltrexone at the level of mechanism, initiation constraint, access, monitoring, and patient preference without prescribing an individual regimen.
• Build a closed-loop discharge plan that protects treatment continuity, overdose prevention, pain care, infection follow-up, and mental health.
• Use naloxone teaching, nonjudgmental safer-use counseling, and emergency thresholds without making abstinence a condition for clinical care.
• Treat insurance, identification, transportation, housing, language, pharmacy supply, and stigma as clinical safety variables with named ownership.

Initial presentation#

River is a 38-year-old nonbinary adult admitted for four days with a painful left forearm infection. They prefer River as their name and use they and them pronouns. The infection began after an injection into a small vein. Imaging did not show a drainable collection, and blood cultures remained negative. The arm improved with antibiotics, elevation, wound care, and repeated examination. The admission was not for an overdose.

On the first hospital night, River developed yawning, sweating, and abdominal cramping. There was loose stool, diffuse aching, restlessness, and a strong urge to leave. They described daily fentanyl use for approximately three years and two nonfatal overdoses, the most recent about four months ago. A friend gave naloxone during one event. River had tried nonprescribed buprenorphine once after using fentanyl and remembered becoming abruptly sicker. They now fear that any buprenorphine will reproduce that experience.

An addiction consultation confirmed a pattern consistent with opioid use disorder, assessed other substances and medical conditions, and discussed treatment choices. River chose a clinician-supervised buprenorphine initiation after the team explained the timing and monitoring plan. Their withdrawal and craving improved. They remained awake, participated in wound care, ate, walked on the unit, and said for the first time that discharge without an immediate return to fentanyl seemed possible.

The transition looks less secure when the details are tested. River has slept in a cousin's living room since losing an apartment. Their phone works only on wireless internet. Their identification card was stolen. The outpatient appointment listed in the discharge template is eight days away, while the inpatient medicine supply ends sooner. The first pharmacy contacted does not stock the prescribed formulation. A second says the insurance record contains a different surname. The cousin can offer a couch for several nights but cannot store medicines in a locked space and has young children at home.

Pain remains another fault line. River rates the arm pain as improved but still significant with dressing changes. They worry that staff will dismiss all pain as drug seeking. The hospital record lists acetaminophen, an anti-inflammatory medicine that was stopped after kidney function worsened briefly, and short-term opioid analgesia early in the admission. River asks whether continuing buprenorphine means nobody will treat severe pain in the future.

River reports intermittent nonprescribed alprazolam use, usually when unable to sleep, and occasional alcohol use. They deny daily benzodiazepine use, prior sedative-withdrawal seizure, or current alcohol withdrawal symptoms, but the frequency is uncertain. They smoke cigarettes and sometimes use methamphetamine. They deny current suicidal intent, plan, or psychosis. They are anxious about discharge and say, "If the medicine runs out, I know what I will do. I do not want to die, but I also cannot be sick on the street."

On the discharge morning River is alert, temperature is normal, pulse is 92 per minute, breathing is unlabored, and oxygen saturation is normal. Pupils are not pinpoint. There is no new sweating, vomiting, diarrhea, or piloerection. There is no marked restlessness, confusion, slurred speech, or nodding. The arm is less red than on admission, distal circulation and movement are intact, and the wound has no new drainage. Kidney function has returned near baseline. The team pauses discharge. The question is no longer whether a prescription can be printed. It is whether treatment, rescue, pain care, infection care, and accountability can cross the hospital door together.

Problem representation#

River is an adult with opioid use disorder involving daily fentanyl use, prior overdose, past severe worsening after an unsupervised buprenorphine attempt, intermittent benzodiazepine and stimulant use, an improving injection-associated soft-tissue infection, ongoing acute pain, temporary housing, unreliable phone access, an identification and insurance mismatch, and a pharmacy supply failure. They chose and tolerated hospital-initiated buprenorphine, with improved withdrawal and craving, but face a likely gap before a receiving appointment.

The immediate clinical task is to verify that River is neither withdrawing nor sedated, reconcile the exact inpatient treatment and last administration, keep pain and infection plans coherent, and prevent an avoidable interruption. The systems task is equally clinical: confirm a lawful, feasible bridge and a reachable receiving team. Confirm stocked pharmacy, coverage resolution, and transport. Confirm records, naloxone, and an outreach plan. The ethical task is to respect River's goals without making housing, toxicology, counseling attendance, or perfect abstinence prerequisites for evidence-based treatment.

Prioritized differential#

1. Opioid use disorder with high transition-related recurrence and overdose risk#

Reasoning for: River describes loss of control, daily use, and craving. River describes withdrawal, continued use despite infections and overdoses, and repeated unsuccessful efforts to stop. The hospital response to buprenorphine supports current physiologic dependence but is not itself the diagnosis. A treatment gap, reduced tolerance, unstable supply, and previous overdose create immediate risk after discharge.

Why it cannot be missed: Detoxification or forced interruption without continuing medication increases the chance of return to use. The drug supply may contain fentanyl or other unexpected substances. A return to the amount previously used after even partial tolerance loss can cause fatal respiratory depression.

2. Recurrent opioid withdrawal or precipitated withdrawal#

Current examination is not consistent with substantial withdrawal. But the last administration time, formulation, and vomiting must be verified. So must adherence and pharmacy access. Withdrawal can cause aching, anxiety, and nausea. It can cause vomiting, diarrhea, and sweating. It can cause piloerection, dilated pupils, and restlessness. It can cause tachycardia and craving. It can be mistaken for infection, panic, uncontrolled pain, or medication-seeking behavior.

Precipitated withdrawal is a specific possibility when a partial agonist displaces a full agonist from receptors before sufficient spontaneous withdrawal, though the actual risk depends on the opioid pattern, timing, physiology, and initiation method. River's prior experience is plausible but not proven from memory alone. It should shape consent and monitoring, not create a lifetime prohibition against a medicine they now tolerate.

3. Opioid intoxication or overdose#

Unresponsiveness, slow or absent breathing, cyanosis, very small pupils, snoring or gurgling in a person who cannot awaken, and falling oxygenation would shift the pathway to airway support, an opioid reversal medicine, emergency response, and investigation of co-ingestants. River is currently awake with normal breathing, so overdose is not present now. Risk remains because of sedatives, variable fentanyl content, treatment interruption, and uncertain tolerance after hospitalization.

4. Sedative co-use, intoxication, or a second withdrawal syndrome#

Intermittent alprazolam use raises additive respiratory, cognitive, fall, and overdose risk. The reported pattern does not establish benzodiazepine dependence, yet uncertainty about frequency and access matters. Daily or heavy sedative use could create a separate dangerous withdrawal risk if stopped abruptly. Alcohol, gabapentinoids, sedating antihistamines, sleep medicines, and other depressants also need direct review. Stimulant use adds sleep loss, anxiety, chest symptoms, psychosis, and cardiovascular risk rather than protecting against opioid sedation.

5. Uncontrolled acute pain, opioid-related hyperalgesia, or a new arm complication#

Pain during dressing change is expected, but worsening pain out of proportion, expanding redness, crepitus, fluctuance, fever, new drainage, loss of movement, sensory change, coolness, or systemic illness would reopen the infection and surgical differential. Compartment syndrome, necrotizing infection, and abscess are not dismissed because opioid use disorder is present. Neither are thrombosis, retained foreign material, and septic arthritis. Neither are osteomyelitis and endocarditis.

Pain may also intensify craving and return-to-use risk. Opioid tolerance can make analgesia more complex, while fear of stigma can delay symptom reporting. The correct response is a measured pain assessment and coordinated plan, not denial of analgesia or an unexamined escalation.

6. Medication adverse effect or interaction#

Buprenorphine can cause sedation, constipation, nausea, headache, and other adverse effects. Methadone has accumulation, interaction, and cardiac-conduction considerations. Naltrexone can precipitate severe withdrawal if given while opioids remain on receptors and blocks opioid analgesia while active. Antibiotics, psychiatric medicines, sedatives, and pain medicines may add interactions or organ constraints. A medication list must be treated as one connected system.

7. Infection and other complications associated with injection#

The improving forearm infection still needs completion of a feasible antibiotic and wound plan. Fever, a new murmur, or embolic findings would raise concern for invasive infection. So would spinal pain, focal neurologic change, persistent bacteremia, or pulmonary symptoms. HIV, hepatitis B, hepatitis C, tetanus status, and sexually transmitted infection testing or prevention are offered according to risk and consent. Screening is paired with ownership of results and treatment linkage.

8. Depression, trauma, anxiety, or suicide risk#

River denies current intent, but the statement about not wanting to die and expecting return to use deserves a direct, private assessment. Overdose can be accidental, intentional, or of uncertain intent. Trauma, grief, and discrimination can change presentation. So can sleep deprivation, stimulant effects, and withdrawal. Mental-health care is integrated without implying that opioid treatment must wait for psychiatric perfection.

Focused history and examination#

The clinician begins with the transition clock. They confirm the last hospital administration, formulation, clinical response, any missed or vomited medicine, and the exact time the outpatient supply would begin. River is asked about craving, withdrawal symptoms, and sedation. The questions cover constipation, nausea, sleep, and adverse effects. The team checks the medication administration record rather than relying on a copied discharge list.

The opioid history names substances without accusation: fentanyl powder or pills, heroin, and prescription products. It names methadone, buprenorphine, and long-acting formulations. Questions cover route, usual pattern, and last use. They cover periods of abstinence, tolerance change, and prior withdrawal. They cover past treatment, reasons treatment stopped, and overdoses. They cover naloxone response and what River values now. The clinician does not demand a complete lifetime confession before providing care.

Every depressant and stimulant is reviewed, including alcohol, benzodiazepines, and gabapentinoids. The review covers sleep products, antihistamines, and xylazine-contaminated supply concerns. It covers cocaine and methamphetamine. Frequency, last use, and source matter. So do withdrawal history, blackouts, and falls. So do seizures and breathing events. The team distinguishes a positive screening result from a diagnosis and asks permission before contacting other prescribers or reviewing outside records, except where law or an immediate emergency requires otherwise.

Pain history includes location, quality, and movement and dressing triggers. It includes sleep, function, trend, and prior response. Examination assesses wound margins, warmth, and tenderness. It assesses fluctuance, crepitus, and drainage. It assesses distal pulses, capillary refill, and sensation. It assesses motor function and joints. Fever, hemodynamic change, and respiratory findings prompt broader infection assessment. So do spinal tenderness, murmur, and peripheral embolic findings.

Withdrawal and sedation are examined as separate dimensions. A structured withdrawal scale can organize observable signs and reported symptoms, but it cannot decide a medication plan alone. The clinician assesses wakefulness, attention, and speech. The assessment covers pupils, breathing rate and effort, and oxygenation. It covers sweating, yawning, and piloerection. It covers tremor, bowel symptoms, restlessness, and pain. Normal oxygenation does not guarantee safety if sedation is deepening, and anxiety alone does not prove withdrawal.

The mental-health assessment asks directly about hopelessness, suicidal thoughts, and intent. It asks about plan, access to lethal means, and prior attempts. It asks about psychosis, severe anxiety, and reasons for living. It also asks whether River feels safe where they will sleep, whether anyone controls their money or medicines, and whether violence or coercion is present. Pregnancy possibility and reproductive goals are discussed privately when biologically relevant, because pregnancy changes treatment coordination but does not remove access to medication.

Transition history is practical: identification, name used by insurer, coverage, pharmacy location and stock, transport, phone and wireless access, message privacy, work, court obligations, food, toileting, medication storage, wound supplies, and after-hours care. The cousin's willingness and limits are asked with River's consent. A support person is not assigned clinical responsibility they did not accept.

Diagnostic strategy#

Diagnose the disorder, not the laboratory result#

Opioid use disorder is identified through a clinical pattern of impaired control, social impairment, risky use, and pharmacologic features in context. Tolerance and withdrawal occurring only during appropriate prescribed therapy do not by themselves establish the disorder. River's history supplies multiple clinically meaningful features beyond a toxicology result.

Urine drug testing can sometimes clarify recent substance presence or an unexpected result, but common immunoassays may miss fentanyl, some benzodiazepines, or methadone unless specifically included. They may miss buprenorphine or other compounds. Detection windows differ, and false positives and negatives occur. A concentration cannot reliably state the time, amount, impairment, or moral worth of the person. Results should open a safety conversation, not trigger abandonment.

The prescription monitoring program may reveal controlled medicines dispensed through participating systems. It cannot show all use, medicines obtained outside the system, or whether a listed medicine was taken. Records, patient report, examination, and direct pharmacy contact are reconciled rather than ranked as honest versus dishonest.

Decide whether an acute syndrome is present#

Withdrawal assessment is repeated if symptoms or timing change. Severe vomiting, dehydration, pregnancy, significant cardiac disease, uncontrolled infection, or concurrent alcohol or benzodiazepine withdrawal may justify a higher level of care even when opioid withdrawal alone is not usually medically catastrophic. Atypical fever, focal findings, or delirium should not be labeled withdrawal without investigation. Neither should hypoglycemia, chest pain, hypoxia, or marked abdominal tenderness.

Suspected overdose is a bedside emergency diagnosis. Treatment is not delayed for a drug screen. Airway and breathing support, an opioid reversal medicine, emergency services, monitoring for recurrent respiratory depression, and evaluation for sedatives or other causes proceed together.

Use targeted medical testing#

No universal laboratory bundle proves readiness for medication. Kidney and liver function and electrolytes are selected when they change a medicine choice, monitoring, or acute care. So are pregnancy testing when relevant, electrocardiography, and infection tests. River's recent kidney change affects pain options. An electrocardiogram may matter if methadone is considered or if other conduction risks are present, but it should not become a blanket barrier to all treatment.

HIV, hepatitis B, and hepatitis C testing is offered with consent and prevention counseling. It is offered with vaccination when appropriate, and a plan for every result. Wound cultures, blood cultures, repeat imaging, or an echocardiogram depend on infection findings rather than on injection history alone. Diagnostic stewardship protects River from both missed disease and reflexive overtesting.

Verify the transition as a clinical test#

The discharge plan is stress-tested before River leaves. A team member calls the receiving clinic and confirms the appointment, location, arrival instructions, identification alternatives, and clinician who will assume responsibility. The pharmacy confirms the exact product is in stock, can process the coverage information, and is open when River arrives. Transport is booked. The written plan names what to do if any link fails.

This verification is as important as a laboratory result because it changes immediate risk. A printed prescription that cannot be filled is not medication access. A referral sent to a fax queue is not a handoff. A phone number that River cannot use is not follow-up.

Progressive results and interpretation#

The hospital pharmacist reaches the insurer and corrects the surname mismatch using a temporary identity process. A nearby pharmacy confirms supply but will close before the original discharge transport arrives. The team changes transport timing and confirms the prescription electronically. The receiving bridge clinic offers an appointment the next morning and agrees to accept the hospital photo identification sheet with River's consent.

The addiction clinician and primary team reconcile the inpatient record. River has tolerated the current buprenorphine plan without sedation or precipitated withdrawal. The clinical response and current examination support continuation rather than an unplanned switch. The outpatient clinician receives the last administration time, formulation, and infection course. The handoff includes kidney trend, pain plan, and screening results still pending. It includes stated goals and pharmacy information.

Targeted toxicology is positive for fentanyl and the expected treatment medicine. A benzodiazepine result is also positive. It does not quantify use or prove intoxication. River explains that the last nonprescribed tablet was several days before admission. The team assesses for sedative dependence and withdrawal, finds no current syndrome, explains additive breathing risk, and arranges follow-up. Treatment is not withheld because the test is imperfect or uncomfortable.

HIV screening is negative. Hepatitis C antibody is reactive, and confirmatory RNA is pending. Hepatitis B testing shows no established immunity. These results are discussed privately. The clinic, not River, owns follow-up of the RNA result and vaccination plan. A result that returns after discharge is entered into a named work queue with outreach through River's chosen contact method.

The wound remains improved. A simpler oral antibiotic plan is selected based on the infection, allergies, kidney recovery, local guidance, and feasibility. Wound supplies are provided. Pain during dressing change responds to preparation, elevation, gentle technique, acetaminophen within safe total use, and a timed multimodal plan. The team documents that severe new pain requires reassessment rather than an automatic conclusion about drug seeking.

River and the cousin receive naloxone devices after hands-on teaching with a trainer. Each can identify unresponsiveness and abnormal breathing, call emergency services, give the product according to its instructions, provide rescue breathing if trained and able, repeat reversal medicine when indicated by the product and response plan, place the person on their side when breathing resumes, and stay until help arrives. River chooses to keep one device in a backpack and one with the cousin.

Teach-back reveals one remaining error. River thinks the next clinic will require a negative drug test to continue medicine. The receiving clinician joins by phone and states that ongoing use will trigger safety assessment and added support, not automatic discharge. That correction matters because fear of expulsion can make a return to use invisible until it becomes fatal.

Management plan#

Continue an effective medication across the boundary#

Buprenorphine is a partial mu-opioid agonist that can reduce withdrawal and craving and lower overdose risk. Initiation requires attention to current physical dependence, recent opioid type and timing, objective and subjective withdrawal, and the chosen strategy. Standard, low-dose, and other initiation approaches exist, but selection belongs to trained clinicians using current guidance. This case does not provide a regimen.

River has already completed a monitored initiation and is clinically stable. The safest default is continuity of the effective plan while the receiving clinician verifies response and constraints. Stopping because the hospital stay ended would create a preventable gap. Counseling and peer support are offered according to River's goals, but declining or lacking those services does not make medication unavailable.

Methadone is a full mu-opioid agonist with strong evidence for reducing withdrawal, craving, and mortality. For opioid use disorder in the United States, ongoing dispensing generally occurs through a certified opioid treatment program, with limited hospital and regulatory exceptions. It may fit a person who prefers daily structured care, has not done well with buprenorphine, or has other clinical priorities. Initiation and adjustment require attention to tolerance, sedation, interactions, accumulation, and cardiac risk. A transfer from stable buprenorphine is not made casually or because one program is more familiar to staff.

Extended-release naltrexone is an opioid antagonist. It can be an option for a person who is no longer physically dependent on opioids, can complete the required opioid-free interval, understands the implications for pain treatment, and prefers an antagonist. Giving it while opioid dependence persists can precipitate severe withdrawal. River currently needs agonist continuity and has acute pain, so an abrupt antagonist transition would be unsafe and inconsistent with their choice.

The choice among these medicines is not a moral hierarchy. It incorporates prior response, current dependence, and overdose history. It incorporates pain, pregnancy, and organ function. It incorporates interactions, access, and daily travel. It incorporates privacy, work, housing, and the person's goals. Duration is individualized. There is no arbitrary finish line after which medication must be stopped to prove recovery.

Manage sedatives without abandoning care#

Benzodiazepines, alcohol, gabapentinoids, and other depressants can add respiratory and cognitive risk to opioids. River receives clear counseling about combinations, driving, operating equipment, and the danger of unknown tablets. The outpatient team verifies whether any benzodiazepine is prescribed and assesses dependence. If dependence is present, abrupt discontinuation may be dangerous and requires a coordinated plan.

The risk of combined depressants is real, but so is the risk of untreated opioid use disorder. Careful medication management, added monitoring, naloxone, prescriber coordination, and treatment of anxiety or insomnia are safer than expulsion. Pharmacy and clinic messages use neutral language so River does not have to trade honesty for access.

Treat pain as pain#

Buprenorphine does not eliminate the duty to treat acute pain. The team uses wound treatment, positioning, and elevation. It uses ice or heat only when appropriate for the condition. It uses physical support, sleep, and nonopioid analgesics after contraindication review. Kidney function, liver disease, bleeding risk, total acetaminophen from all products, and drug interactions shape selection.

Severe pain, surgery, or trauma may require specialist strategies. These include adjustment of the existing medication and, in some situations, additional opioid analgesia with close monitoring. The plan should be coordinated rather than improvised. Undertreatment can cause suffering and treatment departure, while unmonitored escalation can cause sedation. River receives a wallet note naming the current medicine and clinic contact for future emergency teams.

Prevent overdose and other preventable harm#

Naloxone is offered to River and people likely to witness an overdose. Training uses the actual device and includes emergency calling, breathing support, repeat response, observation after reversal, and the possibility that more than one intervention is needed. Naloxone may trigger acute withdrawal, but restoring breathing takes priority.

River receives nonjudgmental counseling that risk rises after treatment interruption or reduced tolerance, when opioids are combined with alcohol or sedatives, when the supply is unfamiliar, and when a person uses alone. Where legal and available, syringe-service and drug-checking programs can provide sterile supplies, wound care, infectious-disease prevention, and links to treatment. These measures do not replace medication, and medication is not withheld from someone who continues to use.

The team offers hepatitis vaccination, HIV prevention discussion, and hepatitis C confirmation and treatment linkage. It offers sexually transmitted infection care, wound follow-up, and reproductive care. Each is offered without turning a long checklist into a condition of discharge.

Make the bridge observable#

The discharge record contains the receiving appointment, named team, and pharmacy confirmation. It contains the medicine continuity plan, transport, and contact preference. It contains the wound plan, pending results, and naloxone teaching. It contains the pain plan and emergency thresholds. The bridge clinic acknowledges receipt. A hospital clinician remains accountable until that acknowledgement occurs.

If River misses the appointment, outreach begins the same day through the agreed confidential methods. The response is to ask what failed, not to close the chart. A pharmacy outage, transportation loss, or arrest triggers another bridge pathway. So does phone disconnection, renewed use, hospitalization, or fear of stigma. Continuity is a property of the system, not a test of River's motivation.

Escalation, referral, and safety net#

Call emergency services for a person who cannot be awakened, has slow, irregular, or absent breathing, has blue or gray lips, makes choking or gurgling sounds while unresponsive, collapses, has a seizure, or develops severe confusion. Give naloxone or another supplied opioid reversal medicine according to the product instructions, support breathing if trained, place the person on their side when appropriate, and stay until help arrives. A temporary response does not cancel the emergency because recurrent respiratory depression or another substance may still be present.

River also needs emergency assessment for rapidly spreading arm redness, pain out of proportion, crepitus, loss of hand movement or sensation, a cold or pale hand, high fever, fainting, severe chest pain, new shortness of breath, coughing blood, new focal weakness, severe spinal pain with weakness or bladder change, or suicidal intent with inability to stay safe.

Same-day clinical contact is needed for recurrent withdrawal, repeated vomiting, inability to keep medicine down, marked sedation, a new medication reaction, lost or stolen medicine, a pharmacy refusal, return to use after tolerance change, worsening wound pain, new drainage, or inability to reach the next appointment. The written plan names the bridge clinic, hospital contact, after-hours line, and local emergency destination.

River is told not to drive when sedated or impaired. The cousin is not asked to monitor breathing overnight as a substitute for emergency care. If housing becomes unavailable, the team activates social work and respite options rather than assuming treatment can be stored and taken safely outdoors.

Communication, shared decisions, and equity#

The clinician says, "You started a treatment that is helping. Our job is to make sure the next dose, clinic, pharmacy, pain plan, and rescue plan exist before you leave. A gap in the system is not a failure by you."

The chart uses opioid use disorder, return to use, and unexpected toxicology result. It avoids addict, dirty, and clean. It avoids drug seeking, manipulative, and noncompliant. Drug-seeking behavior can describe an interpretation rather than a fact and may conceal untreated pain, withdrawal, fear, or a medication access problem. Neutral documentation improves both dignity and diagnostic accuracy.

River is asked how pronouns, name, and language should shape the visit. The same question covers disability, culture, and family. It covers spirituality and prior health-care experiences. Staff use the chosen name while resolving the insurer's legal-name requirement privately. The team explains what information is shared with the cousin and obtains River's permission. A professional interpreter would be used if preferred; a relative would not carry sensitive consent information by default.

Shared decision-making includes all reasonable medication pathways and the risks of no treatment. It does not present one option as a reward for abstinence. River may prefer privacy, daily structure, fewer visits, an antagonist, or the medicine that has already worked. The clinician explains which options are feasible today and what would need to change for another option later.

Housing, identification, and insurance are written in the assessment because each can interrupt treatment. So are pharmacy stock, transportation, and internet access. So are criminal-legal obligations and work. The clinic offers walk-in backup and preserves care after a missed visit. Medication storage is planned with River and the cousin without implying that people with unstable housing are incapable of treatment.

Teach-back asks River to describe the next three steps, what withdrawal and overdose look like, where naloxone is stored, what to do if the pharmacy cannot fill the medicine, and which wound changes require emergency care. Any incorrect answer is treated as a communication failure to repair.

Follow-up and contingencies#

The bridge visit occurs the next morning. The clinician verifies the last administration, current withdrawal and craving, and sedation. The check covers return to use, pain, and wound. It covers antibiotic access, bowel function, and sleep. It covers mood and naloxone location. They review the prescription monitoring record and toxicology only as tools, not as verdicts. River states that craving is lower and the cousin's home remains available for the week.

The pending hepatitis C RNA is positive. A nurse reaches River through the agreed cousin-mediated message that discloses only that a clinic call is needed. At the visit, River receives the result, explanation that infection is treatable, liver assessment, and a direct treatment pathway. Hepatitis B vaccination begins according to the local schedule. HIV prevention options and repeat testing intervals are discussed based on ongoing risk.

Wound follow-up confirms continued improvement. Dressing supplies and antibiotic completion are checked. Pain has decreased. If pain had worsened, the plan would reopen the differential rather than escalating medication remotely. Kidney function is rechecked only if clinically needed after the recent injury and current medicines.

The clinic schedules frequent early contact according to River's stability and preference, then adjusts over time. Visits address medication benefit and harms, craving, and use. They address overdose events, sedatives, and stimulant use. They address pain, infections, and sleep. They address mental health, housing, and goals. Counseling, peer support, and social services remain available without becoming gates.

Contingency branches are explicit:

• Pharmacy cannot dispense the medicine: The clinic speaks directly with the pharmacy, resolves coverage or stock, and identifies a lawful alternative without leaving River to call a list.
• River returns to fentanyl use: The team assesses overdose, sedation, withdrawal, treatment response, and what changed. It increases support and revises the plan rather than ending care.
• River becomes markedly sedated: The plan shifts to emergency breathing assessment, possible reversal, and evaluation of co-use, dose, organ function, or another illness.
• River wants methadone: The clinician explains the opioid treatment program pathway, arranges a direct intake, and coordinates the transition without an unplanned medication gap.
• River wants extended-release naltrexone: The team reviews current dependence, required opioid-free interval, pain implications, contraindications, and overdose risk after discontinuation before any transition.
• River is detained or hospitalized again: With consent and within applicable privacy rules, the team sends the verified treatment record and advocates for uninterrupted medication.
• The cousin's housing ends: Social work, respite, shelter medicine, and flexible clinic options are activated while treatment continues.

Reasoning traps and alternative pathways#

• Calling a printed prescription continuity: Supply, coverage, pharmacy, timing, and a receiving clinician must all work.
• Treating withdrawal management as complete treatment: A short symptom episode can end while the disorder and overdose risk persist.
• Using a toxicology result to punish: Tests have limited detection and timing information and should guide safety, not abandonment.
• Withholding medication because sedatives are present: Co-use raises risk and monitoring needs, but untreated opioid use disorder also causes harm.
• Forcing counseling before medication: Psychosocial care can help, but lack of availability or acceptance should not automatically delay medication.
• Assuming all distress is withdrawal: Infection, pain, panic, stimulant effects, sedative withdrawal, and other illness may coexist.
• Assuming all pain reports seek euphoria: Examine the symptom, treat the cause, and coordinate analgesia.
• Starting naltrexone while physical dependence persists: An antagonist can precipitate severe withdrawal and complicate acute pain.
• Stopping an effective medicine at discharge: Treatment disruption is itself a safety event.
• Teaching naloxone without demonstrating it: Device-specific practice and teach-back expose misunderstandings before an emergency.
• Requiring ideal housing: Adapt storage, visit, and outreach plans rather than excluding people at highest risk.
• Making abstinence the only outcome: Survival, retention, reduced use, fewer infections, improved function, and progress toward the person's goals all matter.

An alternative patient who is currently unresponsive with abnormal breathing needs overdose rescue before any transition discussion. A patient with severe alcohol or benzodiazepine withdrawal may need monitored withdrawal care alongside opioid treatment. A patient stable on methadone should not be forced to switch because the hospital lacks familiarity. A person taking opioids exactly as prescribed for pain without impaired control or harmful use may have physical dependence but not opioid use disorder. The diagnosis and plan must remain individualized.

Evidence limits and what could change#

CDC, SAMHSA, FDA, and ASAM support medication treatment. The medicines are buprenorphine, methadone, or naltrexone. These bodies warn against detoxification alone as treatment for opioid use disorder. Observational syntheses associate retention in methadone and buprenorphine treatment with lower all-cause and overdose mortality, while the periods after treatment cessation carry added risk. Those data strongly support continuity, but observational comparisons cannot remove every difference between people who remain in and leave treatment.

Fentanyl and other high-potency synthetic opioids complicate withdrawal timing and initiation. Multiple buprenorphine initiation strategies are used, and evidence continues to develop about which strategy fits which patient. This case intentionally avoids a universal waiting period or dosing sequence. Local expertise and updated guidance are required.

Federal rules changed to expand access to opioid treatment programs, and the former federal waiver requirement for prescribing buprenorphine was removed. State rules, pharmacy practice, clinician registration, and program capacity can still vary.

Naloxone reverses opioid effects but cannot correct every cause of unresponsiveness, and potent or long-acting opioids may outlast the first response. Emergency evaluation remains necessary. Drug checking and syringe services reduce some harms but do not make an unpredictable supply safe.

River's course is one constructed path. Another person may prefer methadone, qualify for naltrexone after an opioid-free interval, need pregnancy-specific coordination, have severe liver disease, require surgery, live far from any pharmacy, or have a sedative withdrawal syndrome. The completed human review by Jasaman (Jasmin) Tojjar, MD, PhD covered the case, its sources, transition details, and safety language.

Key points#

• Hospital initiation is only the first half of treatment; the next medicine, clinician, pharmacy, transport, records, and contingency plan must be confirmed before discharge.
• Withdrawal, overdose, pain, infection, sedative effects, and psychiatric risk can overlap and require separate assessment rather than one stigmatizing explanation.
• Buprenorphine, methadone, and naltrexone have different mechanisms, initiation constraints, access pathways, and pain implications; patient preference and clinical context guide choice.
• Naloxone, emergency-response teaching, infection prevention, pain care, and safer-use counseling remain necessary even after effective medication begins.
• A return to use, unexpected toxicology result, missed visit, unstable housing, or pharmacy failure should trigger added support and systems repair, not automatic discharge from care.

For your own health, talk with your clinician.*